Saniona AB (publ) (SANION.ST)
SEK 6.3
(0.0%)
SEK 6.3
(0.0%)
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2023 | -69.69 Million SEK | 68.0% |
| 2022 | -195.99 Million SEK | 45.99% |
| 2021 | -398.85 Million SEK | -148.92% |
| 2020 | -64.63 Million SEK | -99.81% |
| 2019 | -68.71 Million SEK | -70.69% |
| 2018 | -53.67 Million SEK | 14.16% |
| 2017 | -55.71 Million SEK | -1100.51% |
| 2016 | 4.54 Million SEK | 119.44% |
| 2015 | -28.49 Million SEK | -308.22% |
| 2014 | -6.97 Million SEK | -461.75% |
| 2013 | -1.22 Million SEK | 43.2% |
| 2012 | -2.18 Million SEK | 0.0% |
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2024 Q1 | -11.55 Million SEK | 53.51% |
| 2024 Q2 | -14.4 Million SEK | -112.65% |
| 2023 Q3 | -15.14 Million SEK | 21.7% |
| 2023 Q2 | -19.34 Million SEK | -2.95% |
| 2023 Q4 | -14.09 Million SEK | 6.95% |
| 2023 FY | - SEK | 68.0% |
| 2023 Q1 | -18.78 Million SEK | 37.06% |
| 2022 Q2 | -85.17 Million SEK | 34.53% |
| 2022 FY | - SEK | 45.99% |
| 2022 Q1 | -130.09 Million SEK | -4.33% |
| 2022 Q4 | -29.84 Million SEK | -209.15% |
| 2022 Q3 | 27.34 Million SEK | 132.1% |
| 2021 FY | - SEK | -148.92% |
| 2021 Q1 | -91.99 Million SEK | -34.29% |
| 2021 Q4 | -124.69 Million SEK | -45.01% |
| 2021 Q3 | -85.99 Million SEK | 15.15% |
| 2021 Q2 | -101.34 Million SEK | -10.16% |
| 2020 FY | - SEK | -99.81% |
| 2020 Q4 | -68.5 Million SEK | -79.69% |
| 2020 Q1 | -30.39 Million SEK | -861.63% |
| 2020 Q2 | -24.97 Million SEK | 17.83% |
| 2020 Q3 | -38.12 Million SEK | -52.64% |
| 2019 Q2 | -20.78 Million SEK | 30.95% |
| 2019 Q4 | -3.16 Million SEK | 88.3% |
| 2019 Q3 | -27.02 Million SEK | -30.04% |
| 2019 FY | - SEK | -70.69% |
| 2019 Q1 | -30.09 Million SEK | -8.75% |
| 2018 Q4 | -27.67 Million SEK | -240.14% |
| 2018 Q2 | -23.96 Million SEK | -53.85% |
| 2018 Q1 | -15.57 Million SEK | -2.82% |
| 2018 Q3 | 19.74 Million SEK | 182.4% |
| 2018 FY | - SEK | 14.16% |
| 2017 Q2 | -17.74 Million SEK | -137.96% |
| 2017 Q4 | -15.15 Million SEK | -1.07% |
| 2017 Q1 | -7.45 Million SEK | 46.46% |
| 2017 Q3 | -14.99 Million SEK | 15.51% |
| 2017 FY | - SEK | -1100.51% |
| 2016 Q2 | -13.42 Million SEK | -1293.87% |
| 2016 Q1 | -963 Thousand SEK | 84.88% |
| 2016 FY | - SEK | 119.44% |
| 2016 Q4 | -13.92 Million SEK | -141.15% |
| 2016 Q3 | 33.84 Million SEK | 352.13% |
| 2015 Q3 | -10.62 Million SEK | -62.81% |
| 2015 Q4 | -6.36 Million SEK | 40.08% |
| 2015 FY | - SEK | -308.22% |
| 2015 Q1 | -4.92 Million SEK | 10.46% |
| 2015 Q2 | -6.52 Million SEK | -32.58% |
| 2014 Q3 | -2.08 Million SEK | -204.82% |
| 2014 FY | - SEK | -461.75% |
| 2014 Q4 | -5.49 Million SEK | -163.74% |
| 2014 Q1 | -787 Thousand SEK | 0.0% |
| 2014 Q2 | -684 Thousand SEK | 13.09% |
| 2013 FY | - SEK | 43.2% |
| 2012 FY | - SEK | 0.0% |
| Name | EBITDA | EBITDA Difference |
|---|---|---|
| Calliditas Therapeutics AB (publ) | -367.8 Million SEK | 81.051% |
| Camurus AB (publ) | 562.54 Million SEK | 112.389% |
| Mendus AB (publ) | -97.84 Million SEK | 28.771% |
| Lipum AB (publ) | -37.11 Million SEK | -87.761% |
| NextCell Pharma AB | -40.98 Million SEK | -70.049% |
| Simris Alg AB (publ) | -22.36 Million SEK | -211.653% |
| Elicera Therapeutics AB (publ) | -17.08 Million SEK | -307.943% |
| Active Biotech AB (publ) | -43.88 Million SEK | -58.806% |
| Amniotics AB (publ) | -27.14 Million SEK | -156.77% |
| Asarina Pharma AB (publ) | -14.21 Million SEK | -390.223% |
| BioArctic AB (publ) | 275.38 Million SEK | 125.308% |
| Cantargia AB (publ) | -284.31 Million SEK | 75.487% |
| Scandinavian ChemoTech AB (publ) | -19.57 Million SEK | -255.968% |
| CombiGene AB (publ) | -35.33 Million SEK | -97.235% |
| Diamyd Medical AB (publ) | -140.85 Million SEK | 50.519% |
| Genovis AB (publ.) | 64.57 Million SEK | 207.934% |
| Guard Therapeutics International AB (publ) | -114.9 Million SEK | 39.347% |
| Isofol Medical AB (publ) | -37.02 Million SEK | -88.243% |
| Intervacc AB (publ) | -68.98 Million SEK | -1.037% |
| Kancera AB (publ) | -61.88 Million SEK | -12.613% |
| Karolinska Development AB (publ) | -26.78 Million SEK | -160.221% |
| LIDDS AB (publ) | -39.67 Million SEK | -75.687% |
| Lipigon Pharmaceuticals AB (publ) | -12.1 Million SEK | -475.801% |
| Magle Chemoswed Holding AB (publ) | 31.4 Million SEK | 321.93% |
| OncoZenge AB (publ) | 7.26 Million SEK | 1059.194% |
| Vicore Pharma Holding AB (publ) | -317.46 Million SEK | 78.046% |
| Xbrane Biopharma AB (publ) | -282.03 Million SEK | 75.288% |
| Xintela AB (publ) | -53.47 Million SEK | -30.342% |
| Xspray Pharma AB (publ) | -169.81 Million SEK | 58.958% |
| Ziccum AB (publ) | -20.34 Million SEK | -242.616% |
| Modus Therapeutics Holding AB (publ) | 2000.00 SEK | 3484850.0% |
| Alligator Bioscience AB (publ) | -237.61 Million SEK | 70.669% |
| Sprint Bioscience AB (publ) | -2.08 Million SEK | -3250.721% |
| QuiaPEG Pharmaceuticals Holding AB (publ) | -13.43 Million SEK | -418.911% |
| Corline Biomedical AB | -1.69 Million SEK | -4021.526% |
| IRLAB Therapeutics AB (publ) | -173.32 Million SEK | 59.789% |
| Bio-Works Technologies AB (publ) | -54.8 Million SEK | -27.167% |
| Aptahem AB (publ) | -10 Million SEK | -596.308% |
| Infant Bacterial Therapeutics AB (publ) | 11.54 Million SEK | 703.472% |
| Fluicell AB (publ) | -25.91 Million SEK | -168.947% |
| Biovica International AB (publ) | -119.5 Million SEK | 41.681% |
| Spago Nanomedical AB (publ) | -42.22 Million SEK | -65.06% |
| AcouSort AB (publ) | -16.7 Million SEK | -317.26% |
| Abliva AB (publ) | -93.6 Million SEK | 25.546% |
| Egetis Therapeutics AB (publ) | -319.1 Million SEK | 78.159% |
| 2cureX AB (publ) | -35.13 Million SEK | -98.358% |
| I-Tech AB | 30.34 Million SEK | 329.675% |
| Hansa Biopharma AB (publ) | -714.55 Million SEK | 90.246% |
| Cyxone AB (publ) | -20.41 Million SEK | -241.408% |
| ExpreS2ion Biotech Holding AB (publ) | -102.45 Million SEK | 31.974% |
| Biosergen AB | 228 Thousand SEK | 30667.982% |
| Nanologica AB (publ) | -62.11 Million SEK | -12.196% |
| SynAct Pharma AB | -222.7 Million SEK | 68.705% |
| Annexin Pharmaceuticals AB (publ) | -43.86 Million SEK | -58.9% |
| BioInvent International AB (publ) | -312.7 Million SEK | 77.712% |
| Stayble Therapeutics AB (publ) | 309.41 Thousand SEK | 22624.91% |
| Alzinova AB (publ) | 41.99 Thousand SEK | 166044.427% |
| Oncopeptides AB (publ) | -231.62 Million SEK | 69.91% |
| Pila Pharma AB (publ) | -8.81 Million SEK | -690.867% |
| Ascelia Pharma AB (publ) | -108.55 Million SEK | 35.799% |
| Diagonal Bio AB (publ) | -11.46 Million SEK | -507.682% |